News
A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...
Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.
Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.
17h
Zacks Investment Research on MSNNovo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US HurdlesNovo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the ...
GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...
1d
Flow Space on MSNLizzo's Weight Loss Reveal Sparks Key GLP-1 AdviceFor example, on a recent episode of the Just Trish podcast, singer, songwriter and rapper Lizzo explained that she tried Ozempic and other GLP-1 drugs at one point in her “weight release” journey but ...
Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).
Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...
Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...
20h
HealthDay on MSNGLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic NeuropathyFor older adults with type 2 diabetes, GLP-1 RA use is associated with nonarteritic anterior ischemic optic neuropathy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results